Sodium valproate, a histone deacetylase inhibitor ameliorates cyclophosphamide-induced genotoxicity and cytotoxicity in the colon of mice

Journal of Basic and Clinical Physiology and Pharmacology

Volumn 25, Issue 4, 2014, Pages 329-339

  Khan, Sabbir ^a   Jena, Gopabandhu ^a  

^a NATIONAL INSTITUTE OF PHARMACEUTICAL EDUCATION AND RESEARCH NIPER   (India)

Author keywords

Colon; Cyclophosphamide; DNA damage; HDAC inhibitor; Sodium valproate

Indexed keywords

8 HYDROXYDEOXYGUANOSINE; CYCLOPHOSPHAMIDE; DNA; HISTONE H2AX; VALPROIC ACID;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CELL PROLIFERATION; COLON; COMET ASSAY; CONTROLLED STUDY; CYTOTOXICITY; DNA DAMAGE; DRUG MEGADOSE; GENOTOXICITY; HISTOPATHOLOGY; IMMUNOHISTOCHEMISTRY; LOW DRUG DOSE; MALE; MOUSE; NONHUMAN; OXIDATIVE STRESS; PROTEIN PHOSPHORYLATION;

EID: 84989837342     PISSN: 07926855     EISSN: 21910286     Source Type: Journal    
DOI: 10.1515/jbcpp-2013-0134     Document Type: Article

References (49)

1. Anderson D, Bishop JB, Garner RC, Ostrosky-Wegman P, Selby PB. Cyclophosphamide: Review of its mutagenicity for an assessment of potential germ cell risks. Mutat Res 1995;330:115-81.
2. Ahmed AR, Hombal SM. Cyclophosphamide (cytoxan): A review on relevant pharmacology and clinical uses. J Am Acad Dermatol 1984;11:1115-26.
3. Hartmann A, Herkommer K, Gluck M, Speit G. DNA-damaging effect of cyclophosphamide on human blood cells in vivo and in vitro studied with the single-cell gel test (comet assay). Environ Mol Mutagen 1995;25:180-7.
4. Harper-Wynne C, English J, Meyer L, Bower M, Archer C, Sinnett HD, et al. Randomized trial to compare the efficacy and toxicity of cyclophosphamide, methotrexate and 5-fluorouracil (CMF) with methotrexate mitoxantrone (mm) in advanced carcinoma of the breast. Br J Cancer 1999;81:316-22.
5. Owari M, Wasa M, Oue T, Nose S, Fukuzawa M. Glutamine prevents intestinal mucosal injury induced by cyclophosphamide in rats. Pediatr Surg Int 2012;28:299-303.
6. Shathish K, Reena D, Guruvayoorappan C. Chemoprotective effect of decalepis hamiltonii against cyclophosphamide induced toxicity. J Exp Ther Oncol 2012;9:291-301.
7. Woo PC, Ng WF, Leung HC, Tsoi HW, Yuen KY. Clarithromycin attenuates cyclophosphamide-induced mucositis in mice. Pharmacol Res 2000;41:527-32.
8. Carew JS, Giles FJ, Nawrocki ST. Histone deacetylase inhibitors: mechanisms of cell death and promise in combination cancer therapy. Cancer Lett 2008;269:7-17.
9. Duenas-Gonzalez A, Candelaria M, Perez-Plascencia C, Perez-Cardenas E, de la Cruz-Hernandez E, Herrera LA. Valproic acid as epigenetic cancer drug: preclinical, clinical and transcriptional effects on solid tumors. Cancer Treat Rev 2008;34:206-22.
10. Arce C, Perez-Plasencia C, Gonzalez-Fierro A, de la Cruz-Hernandez E, Revilla-Vazquez A, Chavez-Blanco A, et al. A proof-of-principle study of epigenetic therapy added to neoadjuvant doxorubicin cyclophosphamide for locally advanced breast cancer. Plos One 2006;1:e98.
11. Kee HJ, Bae EH, Park S, Lee KE, Suh SH, Kim SW, et al. HDAC inhibition suppresses cardiac hypertrophy and fibrosis in DOCA-salt hypertensive rats via regulation of HDAC6/HDAC8 enzyme activity. Kidney Blood Press Res 2013;37: 229-39.
12. Van Beneden K, Geers C, Pauwels M, Mannaerts I, Verbeelen D, van Grunsven LA, et al. Valproic acid attenuates proteinuria and kidney injury. J Am Soc Nephrol 2011;22:1863-75.
13. Rocca A, Minucci S, Tosti G, Croci D, Contegno F, Ballarini M, et al. A phase I-II study of the histone deacetylase inhibitor valproic acid plus chemoimmunotherapy in patients with advanced melanoma. Br J Cancer 2009;100:28-36.
14. Marchion DC, Bicaku E, Daud AI, Sullivan DM, Munster PN. Valproic acid alters chromatin structure by regulation of chromatin modulation proteins. Cancer Res 2005;65:3815-22.
15. Marchion DC, Bicaku E, Daud AI, Sullivan DM, Munster PN. In vivo synergy between topoisomerase ii and histone deacetylase inhibitors: predictive correlates. Mol Cancer Ther 2005;4: 1993-2000.
16. Hess-Stumpp H. Histone deacetylase inhibitors and cancer: from cell biology to the clinic. Eur J Cell Biol 2005;84:109-21.
17. Dong G, Luo J, Kumar V, Dong Z. Inhibitors of histone deacetylases suppress cisplatin-induced p53 activation and apoptosis in renal tubular cells. Am J Physiol Renal Physiol 2009;298:F293-F300.
18. Szyf M. The dynamic epigenome and its implications in toxicology. Toxicol Sci 2007;100:7-23.
19. Hamer HM, Jonkers D, Venema K, Vanhoutvin S, Troost FJ, Brummer RJ. Review article: The role of butyrate on colonic function. Aliment Pharmacol Ther 2008;27:104-19.
20. Comalada M, Bailon E, de Haro O, Lara-Villoslada F, Xaus J, Zarzuelo A, et al. The effects of short-chain fatty acids on colon epithelial proliferation and survival depend on the cellular phenotype. J Cancer Res Clin Oncol 2006;132:487-97.
21. Hu S, Dong TS, Dalal SR, Wu F, Bissonnette M, Kwon JH, et al. The microbe-derived short chain fatty acid butyrate targets miRNA-dependent p21 gene expression in human colon cancer. Plos One 2011;6:e16221.
22. Arany I, Herbert J, Herbert Z, Safirstein RL. Restoration of CREB function ameliorates cisplatin cytotoxicity in renal tubular cells. Am J Physiol Renal Physiol 2008;294:F577-F81.
23. Chung YL, Lee MY, Pui NN. Epigenetic therapy using the histone deacetylase inhibitor for increasing therapeutic gain in oral cancer: prevention of radiation-induced oral mucositis and inhibition of chemical-induced oral carcinogenesis. Carcinogenesis 2009;30:1387-97.
24. Chung YL, Wang AJ, Yao LF. Antitumor histone deacetylase inhibitors suppress cutaneous radiation syndrome: implications for increasing therapeutic gain in cancer radiotherapy. Mol Cancer Ther 2004;3:317-25.
25. Miller AC, Cohen S, Stewart M, Rivas R, Lison P. Radioprotection by the histone deacetylase inhibitor phenylbutyrate. Radiat Environ Biophys 2011;50:585-96.
26. Chong W, Li Y, Liu B, Liu Z, Zhao T, Wonsey DR, et al. Anti-inflammatory properties of histone deacetylase inhibitors: A mechanistic study. J Trauma Acute Care Surg 2012;72:347-54.
27. Ververis K, Karagiannis TC. Potential non-oncological applications of histone deacetylase inhibitors. Am J Transl Res 2011;3:454-67.
28. Chateauvieux S, Morceau F, Dicato M, Diederich M. Molecular and therapeutic potential and toxicity of valproic acid. J Biomed Biotechnol 2010;2010:1-18.
29. Glauben R, Batra A, Fedke I, Zeitz M, Lehr HA, Leoni F, et al. Histone hyperacetylation is associated with amelioration of experimental colitis in mice. J Immunol 2006;176:5015-22.
30. Hu S, Hou JY, Wang HB, Yang M, Sheng ZY. The effect of valproic acid in alleviating early death in burn shock. Burns 2012;38:83-9.
31. Tripathi DN, Jena GB. Ebselen attenuates cyclophosphamideinduced oxidative stress and DNA damage in mice. Free Radic Res 2008;42:966-77.
32. Khan S, Jena GB. Effect of sodium valproate on the toxicity of cyclophosphamide in the testes of mice: influence of pre-And post-Treatment schedule. Toxicol Int 2013;70:68-76.
33. Ohkawa H, Ohishi N, Yagi K. Assay for lipid peroxides in animal tissues by thiobarbituric acid reaction. Anal Biochem 1979;95:351-8.
34. Khan S, Ahmad T, Parekh CV, Trivedi PP, Kushwaha S, Jena G. Investigation on sodium valproate induced germ cell damage, oxidative stress and genotoxicity in male Swiss mice. Reprod Toxicol 2011;32:385-94.
35. Yoshihara K, Yajima T, Kubo C, Yoshikai Y. Role of interleukin 15 in colitis induced by dextran sulphate sodium in mice. Gut 2006;55:334-41.
36. Jahromi SR, Togha M, Fesharaki SH, Najafi M, Moghadam NB, Kheradmand JA, et al. Gastrointestinal adverse effects of antiepileptic drugs in intractable epileptic patients. Seizure 2011;20:343-6.
37. Wagner PG, Welton SR, Hammond CM. Gastrointestinal adverse effects with divalproex sodium and valproic acid. J Clin Psychiatry 2000;61:302-3.
38. Verrotti A, D'Egidio C, Mohn A, Coppola G, Chiarelli F. Weight gain following treatment with valproic acid: pathogenetic mechanisms and clinical implications. Obes Rev 2011;12: E32-e43.
39. Gaspari CN, Guerreiro CA. Modification in body weight associated with antiepileptic drugs. Arq Neuropsiquiatr 2010;68:277-81.
40. Naziroglu M, Yurekli VA. Effects of antiepileptic drugs on antioxidant and oxidant molecular pathways: focus on trace elements. Cell Mol Neurobiol 2013;33:589-99.
41. Ximenes JC, de Oliveira Goncalves D, Siqueira RM, Neves KR, Santos Cerqueira G, Correia AO, et al. Valproic acid: An anticonvulsant drug with potent antinociceptive and anti-inflammatory properties. Naunyn Schmiedebergs Arch Pharmacol 2013;386:575-87.
42. Ximenes JC, Verde EC, da Graca Naffah-Mazzacoratti M, de Barros Viana GS. Valproic acid, a drug with multiple molecular targets related to its potential neuroprotective action. Neurosci Med 2012;3:107-23.
43. Kostrouchova M, Kostrouch Z, Kostrouchova M. Valproic acid, a molecular lead to multiple regulatory pathways. Folia Biol (Praha) 2007;53:37-49.
44. Chen Q, Ouyang DY, Geng M, Xu LH, Zhang YT, Wang FP, et al. Valproic acid exhibits biphasic effects on apoptotic cell death of activated lymphocytes through differential modulation of multiple signaling pathways. J Immunotoxicol 2011;8:210-8.
45. Mah LJ, Orlowski C, Ververis K, Vasireddy RS, El-Osta A, Karagiannis TC. Evaluation of the efficacy of radiation-modifying compounds using gammaH2AX as a molecular marker of DNA double-strand breaks. Genome Integr 2011;2:3.
46. Wilson AJ, Holson E, Wagner F, Zhang YL, Fass DM, Haggarty SJ, et al. The DNA damage mark pH2AX differentiates the cytotoxic effects of small molecule HDAC inhibitors in ovarian cancer cells. Cancer Biol Ther 2011;12:484-93.
47. Kaneko T, Tahara S, Matsuo M. Non-linear accumulation of 8-hydroxy-2′-deoxyguanosine, a marker of oxidized DNA damage, during aging. Mutat Res 1996;316:277-85.
48. Leinonen J, Lehtimaki T, Toyokuni S, Okada K, Tanaka T, Hiai H, et al. New biomarker evidence of oxidative DNA damage in patients with non-insulin-dependent diabetes mellitus. FEBS Lett 1997;417:150-2.
49. Cincarova L, Lochmanova G, Novakova K, Sultesova P, Konecna H, Fajkusova L, et al. A combined approach for the study of histone deacetylase inhibitors. Mol BioSyst 2012;8:2937-45.